News

This multicenter, Phase 2 clinical trial enrolled patients who have not responded well to existing anti-vascular endothelial growth factor (VEGF) therapies including Lucentis®, Avastin® and Eylea®. Top line

If approved, the latest regulatory submission will expand the indications for Imbruvica to a third type of blood cancer. Cilag, a Janssen Pharmaceutical member, and Pharmacyclics Switzerland are

Tarextumab is currently being evaluated in combination with chemotherapy in patients with previously untreated, extensive stage SCLC. The randomized, placebo-controlled Phase II trial will compare progression-free survival (PFS)

Zoptarelin doxorubicin, a novel synthetic peptide carrier linked to doxorubicin, is currently in a ZoptEC (Zoptarelin doxorubicin in Endometrial Cancer) Phase 3 trial in endometrial cancer. Under the

Momenta recently announced the successful completion of Part A of the Phase 1/2 study and has initiated the Part B (Phase 2 proof-of-concept) study. The FDA’s Fast Track

No Serious Adverse Events (SAEs) were observed in the study. Galmed’s Chief Medical Officer, Dr. Maya Halperin stated, "The completion of the analysis adds important data to the

The safety results were consistent with the well-characterized safety profile of fingolimod in relapsing MS (RMS). PPMS is a disorder of the central nervous system (CNS) which affects

The EMA guidance is consistent with the positive feedback the Company received from the US FDA relative to the scope, design and endpoints of the program and the

The goal for a priority review is six months, for a target action date of 30 March 2015, as per the Prescription Drug User Fee Act (PDUFA). In